Table: Daito - 9-MTH group results
Apr 13 (Reuters)-
Daito Pharamaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Feb 28, 2018 Feb 28, 2017 May 31, 2018
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 29.64 27.92 39.50
(+6.2 pct) (+3.4 pct) (+4.0 pct)
Operating 3.19 3.08 4.10
(+3.6 pct) (+11.9 pct) (+7.0 pct)
Recurring 3.25 3.04 4.15
(+6.7 pct) (+6.4 pct) (+7.0 pct)
Net 2.30 2.04 2.85
(+12.6 pct) (+6.9 pct) (+7.3 pct)
EPS 183.81 yen 163.30 yen 227.74 yen
Ann Div 33.00 yen 33.00 yen
-Q2 div 15.00 yen 15.00 yen
-Q4 div 18.00 yen 18.00 yen
NOTE - Daito Pharamaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4577.T
Recent news on Daito Pharmaceutical
See all newsTo Buy Back Up To 4.4% Of Own Shares Worth 2 Billion Yen
Table: Daito Pharmaceutical -Q1 group results
Execution Of JV And Share Transfer Agreement For Transfer Of Kyorin Pharmaceutical's Generic Drug Business To JV By Daito, Meiji Seika Pharma And Dbj
Table: Daito -2025/26 parent results
Table: Daito -2025/26 group results